“Even though drugs like tirzepatide and semaglutide work really well—better than anything we have ever seen—we still have people who don't respond to them,” said Dr. Aronne.

The current trial included a higher percentage of men (35%) than previous trials, especially when compared with the STEP trials involving persons without diabetes, in which 19 to 26% of the ...

Participants using tirzepatide lost 50.3 lbs. (22.8 kg) and participants on Wegovy lost 33.1 lbs. (15.0 kg), on average SURMOUNT-5, a first-of-its-kind head-to-head trial, compared tirzepatide, a ...

Of adults receiving tirzepatide, 94.4% lost at least 5% body weight during the treatment period. From study entry to 84 weeks, the tirzepatide group lost a total of 26.6% body weight.

A new weight loss drug is more effective than medications such as Ozempic and Wegovy, new research suggests. Tirzepatide, which is sold under the brand names Mounjaro and Zepbound – which treat ...

References Lilly’s Zepbound (tirzepatide) superior to Wegovy (semaglutide) in head-to-head trial showing an average weight loss of 20.2% vs 13.7%. News release. Lilly; December 4, 2024.

Researchers collected data from the five SURPASS trials, which assessed the effects of tirzepatide among people with type 2 diabetes. Tirzepatide was compared with placebo in SURPASS-1 and SURPASS ...

In this trial, both drugs helped improve these health markers, but tirzepatide’s added benefits could make it the top choice for many people with obesity. Still, not every patient will need the ...

Even though drugs like tirzepatide and semaglutide work really well, better than anything we have ever seen, we still have people who don't respond to them. So, moving forward, we want to keep ...